ClinicalTrials.gg
WithdrawnNCT02226458AutismUpdated Jan 21, 2022

An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder

A Phase 2 interventional study of EPI-743 in Autism Spectrum Disorder, sponsored by Edison Pharmaceuticals Inc. Withdrawn. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2022-01-21.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Edison Pharmaceuticals Inc (part of PTC Therapeutics) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
This study was halted prior to enrolling.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
3 Years to 14 Years
Sex
All
01

Study summary

The investigators hypothesize that EPI-743 may provide clinical benefit to children with Autism Spectrum Disorder.

Read the detailed description

An Exploratory Open Label Phase 2 Study of EPI-743 (Vincerinone TM) in Children with Autism Spectrum Disorder

02

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Autism
  • Mitochondrial Disorders
  • EPI-743
  • EPI743
  • Rett syndrome
  • Angelman syndrome
03

In context

Autistic Disorder Reclassified

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Lead sponsor

Edison Pharmaceuticals Inc is the lead sponsor of 7 studies on the registry; none are open to participants now.

First submitted before Edison Pharmaceuticals Inc became part of PTC Therapeutics.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
3 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Autism Spectrum Disorder as defined by the criteria for ASD and a gold-standard diagnostic evaluation for ASD such as the Autism Diagnostic Observation Schedule (ADOS) and/or the Autism Diagnostic Interview - Revised (ADI-R)
  2. Male or female, 3 years to 14 years of age
  3. Abnormal glutathione cycle biomarkers (GSH/GSSG in plasma\<8.0)
  4. Language impairment (as defined by the CELF-2 or CELF-4 screener)
  5. Ability to complete language assessment (using either CELF or PLS)
  6. Subject or subject's guardian able to consent and comply with protocol requirements
  7. Abstention from use of Coenzyme Q10, vitamin E, lipoic acid, folinic acid, other forms of folic acid above recommended daily allowance (RDA), and idebenone 2 months prior to treatment with EPI-743 and for duration of study
  8. Stable regimen of medication and supplements for 2 months prior to enrollment and duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Allergy to EPI-743 or sesame oil
  2. Allergy to vitamin E
  3. Clinical history of bleeding or abnormal baseline PT/
  4. Use of anticoagulant medications
  5. Participation in any other interventional study within 90 days of treatment.
  6. Use of antipsychotic medications
  7. Moderate to severe positive response on ABC irritability subscale on questions: Injures self on purpose, is aggressive to other children or adults (verbally or physically), deliberately hurts himself/ herself, and/or does physical violence to self
  8. Severe impairment as defined as a Vineland Adaptive Behavioral Scales composite standard score of \<40
  9. Patients with genetic disease that gives rise to ASD (e.g. Rett syndrome, Down syndrome, fragile x syndrome)
  10. Abnormal liver function tests two times the or renal insufficiency with creatinine levels two times the upper limit of normal
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    EPI-743

    15 mg/kg oral solution three times per day, maximum of 200 mg per dose

    Drug: EPI-743

Interventions

  • Also known as: Vincerinone TM

06

What researchers measure

Primary outcomes

  1. Primary Efficacy

    Change in plasma levels of reduced and oxidized glutathione from baseline to six months

    Time frame: 6 months

Secondary outcomes

  1. Secondary Endpoint

    Change in language skills as assessed by change from baseline to six months on the Clinical Evaluation of Language Fundamentals or Preschool Language Scale

    Time frame: 6 months

  2. Secondary Endpoint

    Change from baseline to six months in adaptive behavior and social skills as assessed by the Vineland Adaptive Behavior Scale-Second Edition (VABS), Social Responsiveness Scale (SRS), and computerized eye movement analysis

    Time frame: 6 months

  3. Secondary Endpoint

    Change from baseline to six months in stereotyped behavior and associated ASD symptoms as assessed by Aberrant Behavior Checklist (ABC), The Ohio Autism Clinical Impression Scale (OACIS), Repetitive Behavior Scale - Revised (RBS-R) and Autism symptoms questionnaire (ASQ)

    Time frame: 6 months

  4. Secondary Endpoint

    Change from baseline to six months in gastrointestinal function as assessed by Symptom Diary (stool frequency, abdominal symptoms and medications) and six-item GI severity index (6-GSI).

    Time frame: 6 months

  5. Secondary Endpoint

    Change from baseline to six months in caregiver strain experienced by parents of children with emotional and behavioral disorders as assessed by Caregiver Strain Questionnaire (CGSQ)

    Time frame: 6 months

  6. Secondary Endpoint

    Change from baseline to six months in intellectual function, attention and memory as assessed by Leiter-R test

    Time frame: 6 months

  7. Secondary Endpoint

    Change from baseline to six months in biomarkers of oxidative stress

    Time frame: 6 months

  8. Secondary Endpoint

    Pharmacokinetic Assessment of EPI-743 including maximal plasma concentration (Cmax), area under plasma concentration curve (AUC), apparent oral clearance, apparent volume of distribution and time to peak concentration

    Time frame: 6 months

  9. Safety Endpoint

    To examine the safety of EPI-743 in subjects with Autism Spectrum Disorder by examining drug-related adverse and serious adverse events

    Time frame: 8 months

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2014 (actual). Primary completion is estimated for Nov 2015, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2014
First posted
Aug 27, 2014
StartActual
Oct 31, 2014
Primary completionEst.
Nov 30, 2015
CompletionEst.
Jan 31, 2016
Last update
Jan 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02226458
Responsible party
Sponsor
First posted
Aug 27, 2014
Start date
Oct 31, 2014
Primary completion
Nov 30, 2015 (estimated)
Completion
Jan 31, 2016 (estimated)
Last update
Jan 21, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion